Detailed explanation of whether filgotinib has entered the domestic market and its listing status

Filgotinib is a selective JAK1 inhibitor mainly used to treat immune-related diseases such as rheumatoid arthritis. Currently, filgotinib has not been approved for marketing by the Food and Drug Administration in mainland China, and patients cannot purchase and use it domestically through formal channels. This current situation leaves patients in need with the only option of purchasing from abroad or waiting for future marketing approval progress.

In the international market, filgotinib has been approved for use in many regions, including Europe and Japan. The original research version is mostly sold under the brand name Jyseleca, and the specifications are usually 200mg×30 tablets per box. The price of the original drug is relatively high, and the European version sells for about more than 10,000 yuan per box. The cost is relatively heavy, which puts a heavy financial burden on many patients.

In addition, there are some cheaper generic versions abroad, especially those produced by the Laos Lucius Company. The specifications are 100mg×30 tablets per box, and the price is about 900 yuan. Although the price advantage is obvious, these generic drugs are different from the original drugs in terms of quality, efficacy consistency and legality. Patients should fully weigh the risks when considering their use.

In general, filgotinib is not yet available in China, and patients need to obtain the drug from foreign channels. Original drugs are more expensive but have guaranteed quality, while generic drugs are more affordable but involve certain risks. When patients choose to purchase, it is recommended to consult a professional doctor and carefully choose the appropriate medication route based on their own condition and economic conditions.

Reference materials:https://www.drugs.com/